Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

1nhaler raises £2 million to develop single-use sustainable inhaler

by November 27, 2023
November 27, 2023
1nhaler raises £2 million to develop single-use sustainable inhaler

1nhaler, a Scotland-based drug delivery device developer, has raised £2 million to develop its unique single-use dry powder inhaler (DPI).

Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but, to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment. 1nhaler has developed a way of enabling many different dry powder drugs to be readily delivered in a sustainable, low-cost delivery device.

Other inhalers are typically made from bulky plastic and are expensive to manufacture and distribute.  1nhaler’s revolutionary sustainable DPI is cardboard-based with the same dimensions as a credit card. The discreet platform technology includes a breathable membrane which can be tailored to deliver individual drugs to patients.

Investment will allow 1nhaler to work with innovative companies around the world, allowing them to bring new and existing drugs to patients in a more efficient and affordable way, opening up the next generation of inhaled products.

The funding round was led by Archangels with support from Dr Yusuf Hamied, British Business Investments (BBI) and seed investors. Dr Hamied, non-executive Chairman of Indian pharmaceutical giant Cipla, is globally respected in the field pioneering the manufacture of affordable drugs for developing countries to fight AIDS and other life-threatening diseases.

Based in Edinburgh, the company was founded by Don Smith and Lisa McMyn in 2017.  They have assembled a team of industry experts, with decades of experience taking inhaled products to market, including Chief Scientific Officer Helen Muirhead who had responsibility for GSK’s blockbuster respiratory portfolio, including the Diskus and Ellipta inhalers.

Lisa McMyn, founder and Chief Executive Officer at 1nhaler, said: “Our DPI has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, revolutionising the delivery of critical drugs, without the cost and environmental impact of existing devices.

“Securing funding from Archangels is invaluable for the next steps in the 1nhaler’s development. Their life sciences expertise and patient capital approach are exactly what we’re looking for in a funding partner.”

Dr Sarah Hardy, Director and Head of New Investments at Archangels, said: “Don, Lisa and the team at 1nhaler have developed a truly innovative technology platform with a clear route to market and opportunity to positively disrupt the status quo of single-dose medicine delivery”.

“We’re proud to add 1nhaler to our portfolio of Scotland’s leading life sciences and technology businesses and look forward to working with them to increase the availability of life-saving drugs affordably and sustainably.”

Operating for over 30 years, Archangels’ investor members have invested over £160 million in the most innovative early-stage companies with disruptive technology, protectable IP and the potential to scale globally.

Archangels has enjoyed a number of significant exits in recent years, including the sale of medical AI business, Blackford Analysis, to Bayer Pharma earlier in the year and the sale of optical platform business, Optoscribe, to Intel Corporation in 2022.

Read more:
1nhaler raises £2 million to develop single-use sustainable inhaler

0
FacebookTwitterGoogle +Pinterest
previous post
Sustainable Scottish chocolatier enjoys sweet success with new premises following support from Business Gateway 
next post
Wazamba Casino Revealed: Our Honest Review on Games & Payouts

You may also like

Sephora Dives Back into the UK Market With...

March 16, 2023

UK in danger of losing British tradespeople to...

July 30, 2023

Asda consults on cutting pay for 7,000 workers

May 19, 2023

BAE Systems to recruit record 2,400 trainees in...

December 2, 2024

Did Ben Elton predict his beloved Labour’s taxing...

January 13, 2025

What Online Casinos Can Teach Entrepreneurs About Customer...

May 20, 2025

Two Fifths of Britons Lack Basic Financial Literacy,...

July 1, 2024

Rolls-Royce boss says net zero is a pain...

October 7, 2022

How to successfully relaunch a web project –...

May 14, 2024

Liz Truss announced as new leader of the...

September 5, 2022

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Trump ally stands firm against ‘big, beautiful bill’ despite pressure: ‘It’ll completely backfire’

      June 8, 2025
    • Rubio condemns assassination attempt on Colombian presidential candidate Miguel Uribe

      June 8, 2025
    • Obama WH physician says Biden doc should have performed cognitive test

      June 8, 2025
    • Trump warns of ‘serious consequences’ if Elon Musk funds Democrats

      June 7, 2025
    • Musk jokes about reconsidering stance on Big Beautiful Bill after Schiff’s praise

      June 7, 2025
    • Musk deletes explosive posts about Trump and Epstein files

      June 7, 2025

    Categories

    • Business (8,152)
    • Investing (2,019)
    • Politics (15,571)
    • Stocks (3,136)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved